Regenerative medicine enters a more evidence-driven phase

Regenerative medicine is moving toward a more evidence-driven phase in which biological plausibility must be separated from demonstrated clinical benefit.

Study design, manufacturing quality, regulation and patient selection all influence how a new intervention should be interpreted.

This demonstration article exists only to validate the English editorial experience of RegenNews.